52 results
8-K
EX-99.1
DRRX
Durect Corp
29 Nov 06
DURECT and Nycomed Sign $202 Million Agreement to Develop and Commercialize POSIDUR™ in Europe and Other Select Countries
12:00am
, this collaboration furthers our objective to become a specialty pharmaceutical company by our retention of commercialization rights in the U.S., as well
S-1
EX-10.13
DRRX
Durect Corp
20 Apr 00
IPO registration
12:00am
for retention in their files. General SOP's or
SOP's serving multiple clients can be reviewed at CBL.
7. All documents generated in support of products … at their request for retention in
their files.
8. A preliminary copy of the production batch record, less the QC section will
be provided
S-1
EX-10.1
cimod44t1uo5uuomat
20 Apr 00
IPO registration
12:00am
PRE 14A
hh2viaqhvle
15 Apr 10
Preliminary proxy
12:00am
S-1
EX-1.1
1sa8fe
20 Apr 00
IPO registration
12:00am